Therapeutic Goods (Medicines Advisory Statements) Specification 2021
8Transitional arrangements
Start here
Get a plain-English read of 8
Turn the raw legal text into a practical explanation grounded in Therapeutic Goods (Medicines Advisory Statements) Specification 2021.
8 Transitional arrangements
(1) In this section:
former specification means the Therapeutic Goods (Medicines Advisory Statements) Specification 2019, as in force immediately before the commencement of this instrument.
transition period means the period beginning on the commencement of this instrument and ending on 30 June 2023.
(2) Despite the repeal of the former specification by this instrument, the former specification continues to apply for the duration of the transition period such that the advisory statements specified in the former specification may continue to be used on a label of a medicine in a prescribed class for the purposes of paragraph 3(5)(ca) of the Act, as an alternative to the advisory statements specified under section 7.
Note: During the transition period, the label of a medicine may contain the applicable advisory statements specified by the former specification instead of the advisory statements specified by this instrument in relation to the medicine. However, once the transition period ceases, the label must contain the advisory statements specified by this instrument in relation to the medicine.